uary. CRISPR hauled in $64 million in April in a round that was led by EFTA00635886 Celgene (NASDAQ: CELG) and the venture arm of GlaxoSmithKline. Caribou Biosciences of Berkeley, CA, too, is part of the fray, having recently raised an $11 million Series A of its own. Editas has become the first of the group not